4D Molecular Therapeutics, Inc. (FDMT)

4D Molecular Therapeutics Stock Forecast

FDMT's stock price has decreased by -87.08% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 9 analysts with 12-month price forecasts for 4D Molecular Therapeutics stock have an average target of 32.33, with a low estimate of 6.00 and a high estimate of 44. The average target predicts an increase of 873.80% from the current stock price of 3.32.

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$6.00	$32.33	$36	$44
Change	+80.72%	+873.80%	+984.34%	+1225.3%

Analyst Ratings

The average analyst rating for 4D Molecular Therapeutics stock from 10 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Dec '24	Jan '25	Feb '25	Mar '25	Apr '25	May '25
Strong Buy	5	5	4	4	4	4
Buy	4	4	4	4	4	4
Hold	1	1	1	1	1	1
Sell	1	1	1	1	1	1
Strong Sell	0	0	0	0	0	0
Total	11	11	10	10	10	10

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Geulah Livshits Chardan Capital	Chardan Capital	Strong Buy Maintains $28 → $25	Strong Buy	Maintains	$28 → $25	+653.01%	May 9, 2025
Salveen Richter Goldman Sachs	Goldman Sachs	Strong Buy Maintains $51 → $44	Strong Buy	Maintains	$51 → $44	+1,225.30%	May 9, 2025
Gena Wang Barclays	Barclays	Buy Maintains $45 → $38	Buy	Maintains	$45 → $38	+1,044.58%	May 9, 2025
Tazeen Ahmad B of A Securities	B of A Securities	Strong Buy Maintains $42 → $40	Strong Buy	Maintains	$42 → $40	+1,104.82%	Mar 10, 2025
Geulah Livshits Chardan Capital	Chardan Capital	Strong Buy Maintains $30 → $28	Strong Buy	Maintains	$30 → $28	+743.37%	Mar 4, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

4.95M

Increased by 13,270.27%

from 37.00K

Revenue Next Year

4.94M

Decreased by -0.18%

from 4.95M

EPS This Year

-3.64

from -2.98

EPS Next Year

-3.93

from -3.64

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	13.61M	18.04M	3.13M	20.72M	37.00K	4.95M	4.94M	4.69M
Revenue Growth	94.85%	32.52%	-82.65%	562.29%	-99.82%	13,270.27%	-0.18%	-4.94%
EPS	-8.82	-2.57	-3.32	-2.58	-2.98	-3.64	-3.93	-3.95
EPS Growth	-	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	13	11	9

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	21.0M	21.0M	21.0M
Avg	4.9M	4.9M	4.7M
Low	n/a	n/a	n/a

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	56,656.8%	324.5%	325.3%
Avg	13,270.3%	-0.2%	-4.9%
Low	-	-	-

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	-3.14	-2.98	-1.63
Avg	-3.64	-3.93	-3.95
Low	-4.61	-5.40	-6.28

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	-	-	-
Avg	-	-	-
Low	-	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.